BACKGROUND: The American Joint Committee on Cancer (AJCC) maintains that the eighth edition of its Staging Manual (AJCC8) has improved accuracy compared with the seventh (AJCC7). However, there are concerns that implementation may disrupt analysis of active clinical trials for stage III patients. We used an independent cohort of melanoma patients to test the extent to which AJCC8 has improved prognostic accuracy compared with AJCC7. METHODS: We analyzed a cohort of 1315 prospectively enrolled patients. We assessed primary tumor and nodal classification of stage I-III patients using AJCC7 and AJCC8 to assign disease stages at diagnosis. We compared recurrence-free (RFS) and overall survival (OS) using Kaplan-Meier curves and log-rank tests. We then compared concordance indices of discriminatory prognostic ability and area under the curve of 5-year survival to predict RFS and OS. All statistical tests were two-sided. RESULTS: Stage IIC patients continued to have worse outcomes than stage IIIA patients, with a 5-year RFS of 26.5% (95% confidence interval [CI] = 12.8% to 55.1%) vs 56.0% (95% CI = 37.0% to 84.7%) by AJCC8 (P = .002). For stage I, removing mitotic index as a T classification factor decreased its prognostic value, although not statistically significantly (RFS concordance index [C-index] = 0.63, 95% CI = 0.56 to 0.69; to 0.56, 95% CI = 0.49 to 0.63, P = .07; OS C-index = 0.48, 95% CI = 0.38 to 0.58; to 0.48, 95% CI = 0.41 to 0.56, P = .90). For stage II, prognostication remained constant (RFS C-index = 0.65, 95% CI = 0.57 to 0.72; OS C-index = 0.61, 95% CI = 0.50 to 0.72), and for stage III, AJCC8 yielded statistically significantly enhanced prognostication for RFS (C-index = 0.65, 95% CI = 0.60 to 0.70; to 0.70, 95% CI = 0.66 to 0.75, P = .01). CONCLUSIONS: Compared with AJCC7, we demonstrate that AJCC8 enables more accurate prognosis for patients with stage III melanoma. Restaging a large cohort of patients can enhance the analysis of active clinical trials.
BACKGROUND: The American Joint Committee on Cancer (AJCC) maintains that the eighth edition of its Staging Manual (AJCC8) has improved accuracy compared with the seventh (AJCC7). However, there are concerns that implementation may disrupt analysis of active clinical trials for stage III patients. We used an independent cohort of melanomapatients to test the extent to which AJCC8 has improved prognostic accuracy compared with AJCC7. METHODS: We analyzed a cohort of 1315 prospectively enrolled patients. We assessed primary tumor and nodal classification of stage I-III patients using AJCC7 and AJCC8 to assign disease stages at diagnosis. We compared recurrence-free (RFS) and overall survival (OS) using Kaplan-Meier curves and log-rank tests. We then compared concordance indices of discriminatory prognostic ability and area under the curve of 5-year survival to predict RFS and OS. All statistical tests were two-sided. RESULTS: Stage IIC patients continued to have worse outcomes than stage IIIA patients, with a 5-year RFS of 26.5% (95% confidence interval [CI] = 12.8% to 55.1%) vs 56.0% (95% CI = 37.0% to 84.7%) by AJCC8 (P = .002). For stage I, removing mitotic index as a T classification factor decreased its prognostic value, although not statistically significantly (RFS concordance index [C-index] = 0.63, 95% CI = 0.56 to 0.69; to 0.56, 95% CI = 0.49 to 0.63, P = .07; OS C-index = 0.48, 95% CI = 0.38 to 0.58; to 0.48, 95% CI = 0.41 to 0.56, P = .90). For stage II, prognostication remained constant (RFS C-index = 0.65, 95% CI = 0.57 to 0.72; OS C-index = 0.61, 95% CI = 0.50 to 0.72), and for stage III, AJCC8 yielded statistically significantly enhanced prognostication for RFS (C-index = 0.65, 95% CI = 0.60 to 0.70; to 0.70, 95% CI = 0.66 to 0.75, P = .01). CONCLUSIONS: Compared with AJCC7, we demonstrate that AJCC8 enables more accurate prognosis for patients with stage III melanoma. Restaging a large cohort of patients can enhance the analysis of active clinical trials.
Authors: G Brancaccio; S Napolitano; T Troiani; R Franco; F Iovino; A Reginelli; F Ciardiello; G Argenziano Journal: Br J Dermatol Date: 2018-10-05 Impact factor: 9.302
Authors: Jean Jacques Grob; Dirk Schadendorf; Paul Lorigan; Paolo Ascierto; James Larkin; Paul Nathan; Caroline Robert; Axel Hauschild; Jeffrey Weber; Adil Daud; Omid Hamid; Reinhard Dummer; Johan Hansson; Christoph Hoeller; Jacob Schachter; Alexander C J Van Akkooi; Claus Garbe Journal: Eur J Cancer Date: 2017-12-07 Impact factor: 9.162
Authors: Prathamesh M Kulkarni; Eric J Robinson; Jing Wang; Yvonne M Saenger; Jaya Sarin Pradhan; Robyn D Gartrell-Corrado; Bethany R Rohr; Megan H Trager; Larisa J Geskin; Harriet M Kluger; Pok Fai Wong; Balazs Acs; Emanuelle M Rizk; Chen Yang; Manas Mondal; Michael R Moore; Iman Osman; Robert Phelps; Basil A Horst; Zhe S Chen; Tammie Ferringer; David L Rimm Journal: Clin Cancer Res Date: 2019-10-21 Impact factor: 12.531
Authors: Babak Ehteshami Bejnordi; Mitko Veta; Paul Johannes van Diest; Bram van Ginneken; Nico Karssemeijer; Geert Litjens; Jeroen A W M van der Laak; Meyke Hermsen; Quirine F Manson; Maschenka Balkenhol; Oscar Geessink; Nikolaos Stathonikos; Marcory Crf van Dijk; Peter Bult; Francisco Beca; Andrew H Beck; Dayong Wang; Aditya Khosla; Rishab Gargeya; Humayun Irshad; Aoxiao Zhong; Qi Dou; Quanzheng Li; Hao Chen; Huang-Jing Lin; Pheng-Ann Heng; Christian Haß; Elia Bruni; Quincy Wong; Ugur Halici; Mustafa Ümit Öner; Rengul Cetin-Atalay; Matt Berseth; Vitali Khvatkov; Alexei Vylegzhanin; Oren Kraus; Muhammad Shaban; Nasir Rajpoot; Ruqayya Awan; Korsuk Sirinukunwattana; Talha Qaiser; Yee-Wah Tsang; David Tellez; Jonas Annuscheit; Peter Hufnagl; Mira Valkonen; Kimmo Kartasalo; Leena Latonen; Pekka Ruusuvuori; Kaisa Liimatainen; Shadi Albarqouni; Bharti Mungal; Ami George; Stefanie Demirci; Nassir Navab; Seiryo Watanabe; Shigeto Seno; Yoichi Takenaka; Hideo Matsuda; Hady Ahmady Phoulady; Vassili Kovalev; Alexander Kalinovsky; Vitali Liauchuk; Gloria Bueno; M Milagro Fernandez-Carrobles; Ismael Serrano; Oscar Deniz; Daniel Racoceanu; Rui Venâncio Journal: JAMA Date: 2017-12-12 Impact factor: 56.272
Authors: Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson Journal: CA Cancer J Clin Date: 2017-10-13 Impact factor: 508.702
Authors: Laura Taylor; Kyle Hood; Lisa Reisch; Joann Elmore; Michael Piepkorn; Raymond Barnhill; Stevan Knezevich; Andrea Radick; David Elder Journal: J Cutan Pathol Date: 2018-05-29 Impact factor: 1.587
Authors: Douglas Grossman; Nwanneka Okwundu; Edmund K Bartlett; Michael A Marchetti; Megan Othus; Daniel G Coit; Rebecca I Hartman; Sancy A Leachman; Elizabeth G Berry; Larissa Korde; Sandra J Lee; Menashe Bar-Eli; Marianne Berwick; Tawnya Bowles; Elizabeth I Buchbinder; Elizabeth M Burton; Emily Y Chu; Clara Curiel-Lewandrowski; Julia A Curtis; Adil Daud; Dekker C Deacon; Laura K Ferris; Jeffrey E Gershenwald; Kenneth F Grossmann; Siwen Hu-Lieskovan; John Hyngstrom; Joanne M Jeter; Robert L Judson-Torres; Kari L Kendra; Caroline C Kim; John M Kirkwood; David H Lawson; Philip D Leming; Georgina V Long; Ashfaq A Marghoob; Janice M Mehnert; Michael E Ming; Kelly C Nelson; David Polsky; Richard A Scolyer; Eric A Smith; Vernon K Sondak; Mitchell S Stark; Jennifer A Stein; John A Thompson; John F Thompson; Suraj S Venna; Maria L Wei; Susan M Swetter Journal: JAMA Dermatol Date: 2020-09-01 Impact factor: 10.282
Authors: Matthew C Hynes; Paul Nguyen; Patti A Groome; Yuka Asai; Meaghan E Mavor; Tara D Baetz; Timothy P Hanna Journal: BMC Cancer Date: 2022-07-01 Impact factor: 4.638
Authors: Paolo A Ascierto; Michael B Atkins; Alexander M Eggermont; Jeffrey E Gershenwald; Jean-Jacques Grob; Omid Hamid; Vernon K Sondak; Jeffrey A Sosman; Hussein A Tawbi; Jeffrey S Weber; Corrado Caracò; Iman Osman; Igor Puzanov Journal: J Transl Med Date: 2021-04-07 Impact factor: 5.531
Authors: Aaron S Farberg; Justin W Marson; Alex Glazer; Graham H Litchman; Ryan Svoboda; Richard R Winkelmann; Nicholas Brownstone; Darrell S Rigel Journal: Dermatol Ther (Heidelb) Date: 2022-03-30